- Home
- ITRG vs SCTX Comparison
ITRG vs SCTX Comparison
Compare ITRG & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | SCTX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.9M | 536.5M |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ITRG | SCTX |
|---|---|---|
| Price | $2.43 | $19.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $6.13 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.4M | 513.6K |
| Earning Date | 11-05-2026 | 11-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.41 | N/A |
| Revenue Next Year | $24.58 | N/A |
| P/E Ratio | $45.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $13.50 |
| 52 Week High | $4.87 | $39.60 |
Technical Indicators
Market Signals| Indicator | ITRG | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 43.87 |
| Support Level | $2.38 | $19.09 |
| Resistance Level | $2.96 | $26.50 |
| Average True Range (ATR) | 0.11 | 2.58 |
| MACD | -0.03 | 0.33 |
| Stochastic Oscillator | 35.11 | 62.93 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.